Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Litapiprant Tablet
Litapiprant · 1 trial · 1 indication
To assess the safety and tolerability after a single dose of Litapiprant Tablets
| Arm | Type | Description |
|---|---|---|
| 25mg single doses | PLACEBO_COMPARATOR | Intervention Drug: 25mg Litapiprant Tablet administered orally once daily Intervention Drug: Matching Placebo Tablet administered orally once daily |
| 50mg single doses | PLACEBO_COMPARATOR | Intervention Drug: 50mg Litapiprant Tablet administered orally once daily Intervention Drug: Matching Placebo Tablet administered orally once daily |
| 100mg single doses | PLACEBO_COMPARATOR | Intervention Drug: 100mg Litapiprant Tablet administered orally once daily Intervention Drug: Matching Placebo Tablet administered orally once daily |
| 200mg single doses | PLACEBO_COMPARATOR | Intervention Drug: 200mg Litapiprant Tablet administered orally once daily Intervention Drug: Matching Placebo Tablet administered orally once daily |
| 400mg single doses | PLACEBO_COMPARATOR | Intervention Drug: 400mg Litapiprant Tablet administered orally once daily Intervention Drug: Matching Placebo Tablet administered orally once daily |
| 600mg single doses | PLACEBO_COMPARATOR | Intervention Drug: 600mg Litapiprant Tablet administered orally once daily Intervention Drug: Matching Placebo Tablet administered orally once daily |
| 800mg single doses | PLACEBO_COMPARATOR | Intervention Drug: 800mg Litapiprant Tablet administered orally once daily Intervention Drug: Matching Placebo Tablet administered orally once daily |
| Name | Type | Description |
|---|---|---|
| Litapiprant Tablet | DRUG | Small molecules inhibitors of the chemoattractant receptor homologous molecule expressed on Th2 cells |
Inclusion Criteria: * Male or female, overall healthy subjects，female VS male 1:1 ratio; * Between 18 and 45 years of age, inclusive, similar ages; * Body weight should be≥50 kg; Body Mass Index (BMI) is between 19.0 and 28.0 kg/m2, inclusive; * Able to comprehend and sign the ICF voluntarily prior...
Top 16 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 10 | PHASE3 | Trelegy Ellipta, Depemokimab, HFA-152a, GSK5784283, Ventolin |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Dupilumab, Lunsekimig |
| AstraZeneca PLC | AZN | 28 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Pfizer Inc. | PFE | 4 | PHASE3 | Tilrekimig, PF-07275315, PF-08103402 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
Litapiprant is an investigational small molecule drug being developed by Sunshine Biopharma Inc. (ticker SBFM) for asthma, a respiratory condition. It is in Phase 1 clinical development and has been studied in a completed Phase 1 trial in healthy volunteers.
Litapiprant is being developed for the treatment of asthma. It is an investigational therapy and has not been approved for any indication. The completed Phase 1 trial enrolled healthy volunteers rather than patients with asthma.
Litapiprant is being developed by Sunshine Biopharma Inc., which trades under the ticker symbol SBFM. The company is the sponsor of the clinical program for this investigational asthma drug.
Litapiprant is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The drug remains investigational and has not been approved by the FDA or any other regulatory agency.
Litapiprant has been evaluated in one completed Phase 1 trial, NCT03663686, titled a safety, tolerability and pharmacokinetic study of Litapiprant tablets in healthy male and female subjects. The trial enrolled 60 participants in China and was randomized, double-blind, and placebo-controlled.
Yes, Litapiprant Tablet is an alternative name for Litapiprant. The Phase 1 trial NCT03663686 studied Litapiprant tablets, which is the oral tablet formulation of the investigational drug being developed by Sunshine Biopharma Inc. for asthma.